OncoMatch/Clinical Trials/Leukemia — Chronic Myeloid (CML)
Leukemia — Chronic Myeloid (CML) Clinical Trials
OncoMatch filters Leukemia — Chronic Myeloid (CML) trials by the molecular markers that determine eligibility — BCR, ABL1, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout Leukemia — Chronic Myeloid (CML) trials
Chronic myeloid leukemia is defined by the Philadelphia chromosome (the BCR-ABL1 fusion arising from the t(9;22) translocation). BCR-ABL1 fusion testing evaluates both partner genes and is the primary lab assay for diagnosis and for minimal-residual-disease monitoring. Quantitative PCR for the BCR-ABL1 transcript level is the basis for tracking response (major molecular response, MR4, MR4.5) and for guiding TKI switches.
Front-line CML trials test TKI sequencing strategies and treatment-free remission protocols. Resistance and intolerance trials match patients to TKI generations based on BCR-ABL1 mutation profile (the T315I mutation requires ponatinib or asciminib). Asciminib trials in earlier lines test the STAMP-inhibitor mechanism as front-line or post-failure standard. Blast-phase CML trials test combinations of TKI with chemotherapy or allogeneic transplant strategies. Pediatric CML trials run through cooperative-group networks separately from adult trials.
CML trial intake usually checks disease phase, TKI line history, and BCR-ABL1 mutation profile. Disease phase (chronic, accelerated, or blast) determines which trial set applies. Prior TKI exposure: most R/R trials specify which TKIs the patient has received and the reason for discontinuation (resistance, intolerance, or suboptimal response). BCR-ABL1 kinase domain mutation testing for T315I and other resistance variants is required for next-generation TKI trials. Prior allogeneic stem cell transplant for post-transplant trials. Performance status, with most CML trials accepting ECOG 0-2.
Biomarkers tested in Leukemia — Chronic Myeloid (CML) trials
These are the molecular markers most commonly required or evaluated in Leukemia — Chronic Myeloid (CML) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Leukemia — Chronic Myeloid (CML) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Ascentage Pharma Group Inc.
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Terns, Inc.
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Augusta University
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
How OncoMatch finds Leukemia — Chronic Myeloid (CML) trials for you
AI reads the protocol
Every Leukemia — Chronic Myeloid (CML) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Leukemia — Chronic Myeloid (CML) and mark your biomarker results — BCR, ABL1 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.